Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Zacks.com on MSN1d
All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy
PLIANT THERAPT (PLRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pliant stock jumps 28% on bexotegrast study update
Pliant Therapeutics (PLRX) stock jumped 21% Thursday after the company issued an update for a Phase 2b clinical study of ...
Hosted on MSN4d
Citigroup Downgrades Pliant Therapeutics (PLRX)
Fintel reports that on February 10, 2025, Citigroup downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy ...
Fintel on MSN4d
Canaccord Genuity Downgrades Pliant Therapeutics (PLRX)
Fintel reports that on February 10, 2025, Canaccord Genuity downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) ...
Pliant Therapeutics: Strange Volatility
Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.
Pliant Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - PLRX
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant ...
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $17.75 Consensus Price Target from Brokerages
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been given an average rating of “Hold” by the eleven analysts that are presently covering the company, Marketbeat reports.
Equities Analysts Issue Forecasts for PLRX FY2029 Earnings
Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Pliant Therapeutics in a report released on Monday, February 10th. HC Wainwright analyst E. Arce ...